Avidity Partners Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-1,784,000
Closed -$23.2M 118
2021
Q1
$23.2M Sell
1,784,000
-216,000
-11% -$3.13M 0.64% 54
2020
Q4
$27.7M Sell
2,000,000
-1,564,900
-44% -$22.8M 0.9% 41
2020
Q3
$52.5M Buy
3,564,900
+1,090,301
+44% +$15.8M 2.44% 11
2020
Q2
$40.2M Buy
2,474,599
+1,292,599
+109% +$20.7M 2.58% 10
2020
Q1
$17.2M Buy
1,182,000
+950,000
+409% +$16.8M 2.37% 15
2019
Q4
$4.7M Buy
+232,000
New +$2.14M 2.96% 15

Other funds holding AUPH

Avidity Partners Management's AUPH Position: Q2 2021 in Review

Avidity Partners Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2021, closing a stake of 1,784,000 shares — an estimated $23.2M sold.

Avidity Partners Management first reported a position in AUPH in Q4 2019 and held it in 6 quarters. The position peaked at $52.5M in Q3 2020. 167 funds tracked by Wall St. Rank hold AUPH as of Q2 2021.

  • Avidity Partners Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Avidity Partners Management sold 1,784,000 Aurinia Pharmaceuticals shares in Q2 2021, an estimated $23.2M.
  • Avidity Partners Management first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Avidity Partners Management's Aurinia Pharmaceuticals position peaked at $52.5M in Q3 2020.
  • 167 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2021.

Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.